research use only

Ritlecitinib (PF-06651600) JAK3 Inhibitor

Cat.No.S8538

Ritlecitinib (PF-06651600) is a potent and irreversible JAK3-selective inhibitor with an IC50 of 33.1 nM but without activity (IC50 > 10 000 nM) against JAK1, JAK2, and TYK2.
Ritlecitinib (PF-06651600) JAK inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 285.34

Quality Control

Chemical Information, Storage & Stability

Molecular Weight 285.34 Formula

C15H19N5O

Storage (From the date of receipt)
CAS No. 1792180-81-4 Download SDF Storage of Stock Solutions

Synonyms N/A Smiles CC1CCC(CN1C(=O)C=C)NC2=NC=NC3=C2C=CN3

Solubility

In vitro
Batch:

DMSO : 57 mg/mL ( (199.76 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 46 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
JAK3 [1]
(Cell-free assay)
33.1 nM
In vitro
Ritlecitinib (PF-06651600) is a newly discovered potent JAK3-selective inhibitor, highly efficacious at inhibiting γc cytokine signaling, which is dependent on both JAK1 and JAK3. In vitro, it inhibits Th1 and Th17 cell differentiation and function. In total lymphocytes in human whole blood, this compound inhibits the phosphorylation of STAT5 elicited by IL-2, IL-4, IL-7, and IL-15 with IC50 values of 244, 340, 407, and 266 nM, respectively, and it inhibits the phosphorylation of STAT3 elicited by IL-21 with an IC50 of 355 nM[1].
In vivo
Ritlecitinib (PF-06651600) reduces disease pathology in rat adjuvant-induced arthritis as well as in mouse experimental autoimmune encephalomyelitis models in vivo. This compound has suitable pharmacokinetics and pharmacodynamics properties for preclinical and clinical evaluations. Its human pharmacokinetics are predicted to show approximate values of blood clearance of 5.6 mL/min/kg, a steady state volume of distribution of 1.3 L/kg, oral bioavailability of 90%, and a systemic half-life of 2 h[1].
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04390776 Completed
Healthy Participants
Pfizer
September 28 2020 Phase 1
NCT04266509 Completed
Healthy Volunteers
Pfizer
June 25 2020 Phase 1
NCT04037865 Terminated
Renal Impairment
Pfizer
August 19 2019 Phase 1
NCT04016077 Completed
Hepatic Impairment|Healthy Participants
Pfizer
July 19 2019 Phase 1
NCT04004663 Completed
Healthy Volunteers
Pfizer
July 15 2019 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Signaling Pathway Map